BY-101921

N/A

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameBY-101921
Drug Alias NameBY101921BY-101921
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTCDD-inducible poly [ADP-ribose] polymerase inhibitors
TargetsTCDD-inducible poly [ADP-ribose] polymerase
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChengdu Baiyu Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesKangbaida (Sichuan) Biopharmaceutical Technology Co LtdChengdu Baiyu Jingelai Pharmaceutical Co LtdChengdu Baiyu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A